One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge  by Klausberger, Miriam et al.
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a  b  s  t  r  a  c  t
Human  infections  with  a novel  inﬂuenza  A  H7N9  subtype  virus  were  reported  in  China  recently.  The  virus
caused  severe  disease  with  high  mortality  rates  and  it raised  concerns  over  its pandemic  potential.  Here,
we  assessed  in  the mouse  model  protective  efﬁcacy  of single  immunisations  with  low  vaccine  doses  of
insect  cell-derived  H7  virus-like  particles,  consisting  of hemagglutinin  and  matrix  protein.  Vaccinated
mice  were  fully  protected  and  survived  a stringent  lethal  challenge  (100  mLD50)  with  H7N9,  even  after  a
single,  unadjuvanted,  low  vaccine  dose  (0.03  g). Serum  analysis  revealed  broad  reactivity  and  hemag-eywords:
nﬂuenza
7N9
andemic
irus-like particle
aculovirus
ross-reactivity
glutination  inhibition  activity  across  a panel  of  divergent  H7 strains.  Moreover,  we  detected  signiﬁcant
levels  of  cross-reactivity  to related  group  2  hemagglutinins.  These  data  demonstrate  that  virus-like  par-
ticle  vaccines  have  the  potential  to induce  broadly  protective  immunity  against  the novel  H7N9  virus  and
a  variety  of  other  H7  strains.
© 2013 The Author. Published by Elsevier Ltd. Open access under CC BY license.. Introduction
On March 31, 2013 the Chinese public health authorities
eported three cases of laboratory-conﬁrmed human infection with
 novel avian-origin inﬂuenza A H7N9 virus [1]. Two  patients in
hanghai and one in the surrounding Anhui province were hos-
italised with symptoms of cough, dyspnoea and high fever and
eveloped acute respiratory distress syndrome (ARDS) and pneu-
onia complications, which proved to be deadly [2]. As of October
5, 2013 [3], 137 human cases of inﬂuenza A H7N9 infection were
eported to the WHO, including 45 deaths. This is the highest mor-
ality number attributed to H7 infections worldwide to date. Efforts
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Open access under CC BY license.to restrict avian to human transmission were initiated includ-
ing shutting down large poultry markets throughout the country.
Antivirals are currently the only prophylactic and therapeutic
options available for human use. Since the novel H7N9 strains are
resistant to M2 ion channel blockers [2,4], neuraminidase inhibitors
are recommended as frontline therapeutic by the Chinese Center for
Disease Control and Prevention [5]. However, oseltamivir-resistant
viruses have been associated with antiviral treatment and poor
clinical outcome [6,7]. The exceptional adaptive ability of the virus
and the lack of human pre-immunity and of available vaccines
underline the necessity of rapid measures to be taken and research
on the development on human H7 vaccines is underway [8–14].
Here,  we assess the efﬁcacy of a single low vaccine dose of
inﬂuenza A H7 virus-like particles (VLPs) of Avian Inﬂuenza A
(H7N9) virus origin to protect against a stringent viral challenge in
the mouse model. Two-component inﬂuenza virus-like particles,
containing HAs from the ﬁrst H7N9 virus isolates (A/Anhui/1/13
or A/Shanghai/1/13, respectively) and the matrix protein (M1)
from A/Udorn/307/1972, were produced in the Trichoplusia ni
insect cell line High Five (BTI-TN-5B1-4) using the baculovirus
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xpression system. Previous studies conclusively demonstrated the
otent immune stimulating properties of live baculovirus in vac-
ine preparations [15,16]. Hence, in order to keep the by-product
n the vaccine formulation, we concentrated the VLPs and residual
aculovirus from the culture supernatant by one-step sucrose-
ushion puriﬁcation. Mice received one VLP vaccine dose
ontaining different amounts of HA (3 g, 0.3 g and 0.03 g)
nd 5 weeks later were challenged with a stringent viral dose
100 mLD50) of the A/Shanghai/1/13 H7N9 strain. Pre-challenge
erum was evaluated for the breadth of reactivity and hemagglu-
ination inhibition (HI) activity of the elicited humoral response
o divergent H7 HAs, as well as representatives of all group 2 HA
ubtypes.
Even the lowest tested vaccine doses conferred full protection
gainst the stringent viral challenge. In addition, a single vacci-
ation with the H7 VLP vaccine induced serum antibodies that
ere broadly reactive and HI active against divergent H7 subtyped
iruses. We  also detected sero-reactivity to heterosubtypic mem-
ers of the group 2 HAs, such as H15 and H3.
. Materials and methods
.1.  Insect cells
Sf9  insect cells (ATCC # CRL-1711) were routinely propagated
t 27 ◦C in TNM-FH medium (Gemini Bio-Products, West Sacra-
ento, CA) supplemented with 0.1% (v/v) Pluronic 68 (Sigma, St.
ouis, MO), 10% (v/v) foetal bovine serum (FBS) (Atlanta Biologi-
als, Norcross, GA) and Penicillin–Streptomycin antibiotic mixture
Life Technologies, Carlsbad, CA). For baculovirus ampliﬁcation,
he medium was switched to 3% (v/v) FBS. BTI-TN-5B1-4 (High
ive – Vienna Institute of Biotechnology subclone) [17] cells were
sed for expression of VLPs and maintained at 27 ◦C in custom
odiﬁed serum-free IPL-41 medium (PAN-Biotech GmbH, Aiden-
ach, Germany) at 27 ◦C as described in [18] supplemented with
enicillin–Streptomycin antibiotic mixture.
.2. Viruses
Recombinant inﬂuenza viruses were generated by reverse
enetics as described before [19–21]. Recombinant A/Puerto
ico/8/34 (PR8) viruses (6:2) were generated that expressed
A and NA of human H7N9 viruses from the current outbreak
n China, including A/Shanghai/1/13 (abbreviated PR8:SH1) and
/Anhui/1/13 (PR8:AH1). The nucleotide sequences of the HA
nd NA of SH1 and AH1 were downloaded from the GISAID
piﬂu database (accession numbers EPI439486 and EPI439507,
espectively). Gene synthesis was conducted by GeneArt (Life
echnologies, Carlsbad, CA). SH1 and AH1 HA and NA sequences
ere subcloned into the ambisense rescue plasmid pDZ for res-
ue of recombinant inﬂuenza viruses. Additional recombinant PR8
irus (7:1) were generated that expressed the HA of the H7
urasian lineage virus A/mallard/NL/12/00 (H7N3; PR8:malNL00),
r the HA of A/chicken/Jalisco/12283/12 (H7N3; PR8:chickJal12)
hich was genetically modiﬁed to remove the multibasic cleav-
ge site. An additional recombinant PR8 viruses was  included
hat expressed a chimeric cH7/3 HA in which the globular head
omain was derived from the H7 North American lineage virus
/mallard/Alberta/24/01 (H7N3; PR8:malAlb01) on an H3 stalk
21,22]. Viruses were propagated in 8- to 10-day-old speciﬁc
athogen-free embryonated chicken eggs (Charles River Labora-
ories) for 48 h at 37 ◦C and virus was titred on MDCK cells in the
resence of tosyl phenylalanyl chloromethyl ketone (TPCK) treated
rypsin.e 32 (2014) 355– 362
2.3.  Production of virus-like particles in insect cells
Synthesised SH1 and AH1 HA genes (GISAID Epiﬂu database
accession numbers EPI439486 and EPI439507, respectively) and
the matrix protein (M1) gene from strain A/Udorn/307/72
(H3N2) (GenBank: DQ508932.1), synthesised by Sloning (Puch-
heim, Germany), were cloned as previously described [17]. VLPs
consisting of the respective H7 HA (either AH1 or SH1) and the
matrix protein (M1) from the unrelated H3N2 subtype were pro-
duced by baculovirus infection of insect cells as described before
[17]. Empty VLPs consisting of M1  only were prepared to be used
as a negative control.
Brieﬂy,  the synthetic genes were cloned into a modiﬁed pFast-
BacDual baculovirus transfer vector and recombinant bacmids
were constructed using the Bac-to-Bac System (Invitrogen, Carls-
bad, CA). Recombinant baculovirus was rescued from Sf9 cells and
ampliﬁed. VLPs were expressed in High Five cells using Fernbach
ﬂasks incubated at 27 ◦C. Cells were infected with the recombi-
nant baculoviruses at a multiplicity of infection of approximately
5 and culture supernatant was  harvested 4 days post infection by
low-speed centrifugation (3.000 rpm, 10 min). VLPs were partially
puriﬁed and concentrated using a 30% (w/v) sucrose cushion in
phosphate buffered saline (PBS) and the pellet was resuspended
in PBS and stored at 4 ◦C.
2.4.  Western blot analysis and HA quantiﬁcation
To quantify the HA content of the VLPs, different concentra-
tions of VLP samples were compared to known concentrations
of recombinant His-tag puriﬁed SH1-HA containing a T4 foldon
trimerisation domain [23]. VLP and His-tag HA were separated by
SDS-PAGE using 4–12% gradient polyacrylamide gels (Invitrogen,
Carlsbad, CA). After electrophoretic transfer onto polyvinylidene
diﬂuoride (PVDF) membranes (Thermo Fisher Scientiﬁc, Waltham,
MA), the membranes were blocked for 1 h in PBS containing 0.1%
Tween 20 (v/v) (PBST) and 3% (w/v) non-fat dry milk powder.
After three washes with PBST, the blots were incubated for 3 h
with convalescent serum obtained from mice sublethally infected
with SH1 at a dilution of 1:1000. Membranes were washed three
times with PBST and incubated for 1 h at room temperature
with a horseradish-peroxidase-conjugated goat anti-mouse IgG
(H + L) secondary antibody (Santa Cruz Biotechnology, Inc., Dal-
las, TX) at a dilution of 1:2000. Then, membranes were rinsed
again and protein bands were visualised using the two-component
Western Lightning® Plus-ECL enhanced chemiluminescence sub-
strate kit (PerkinElmer, Inc., Waltham, MA)  and Ultra CruzTM
Autoradiography Blue Films (Santa Cruz Biotechnology, Inc., Dal-
las, TX). Radiographs were developed on a SRX-101A processor
(Konica Minolta, Osaka, Japan). HA content of the VLP samples
was determined densitometrically against known concentra-
tions of the SH1-HA protein using ImageJ (National Institutes of
Health).
2.5. Hemagglutination assay
Two-fold serial dilutions of PR8:AH1, PR8:SH1, PR8:malNL00,
PR8:malAlb01 and PR8:chickJal12 recombinant reassortant virus
strains in PBS (50 L) were prepared in Nunc® 96-well polystyrene
V-bottom microwell plates (Thermo Fisher Scientiﬁc, Waltham,
MA), followed by the addition of 50 L 0.5% (v/v) chicken or turkey
red blood cells (RBCs) (Lampire Biological Laboratory, Pipersville,
PA) in PBS into each well. RBCs were allowed to settle for 45–60 min
at 4 ◦C and the HA titre was  determined by visual inspection.
Hemagglutination units (HAU) are read as the reciprocal of the last
dilution, giving rise to hemagglutination of red blood cells.
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.6. Quantiﬁcation of baculovirus content in the vaccine
reparation
Baculovirus titres in the VLP vaccine doses were determined by
laque assay on Sf9 cells with minor modiﬁcations as described in
24]. Brieﬂy, the assay was carried out in 6-well plates in duplicates.
fter seeding 1 × 106 cells per well, the cells were allowed to attach
o the surface, medium was removed and 200 L of the diluted
LP vaccine formulations (10-fold dilutions in TNM-FH unsupple-
ented) were added and incubated for 1 h at 27 ◦C with periodic
haking. After infection, the samples were removed and cells were
verlaid with 2 mL  of a solution containing 1% agarose in TNM-FH,
0% (v/v) foetal bovine serum, Penicillin–Streptomycin antibiotic
ixture pre-warmed to 37 ◦C. The plates were incubated at 27 ◦C
or 6 days and plaques were counted after live-cell staining with
00 L of 5 mg/mL  Thiazolyl blue formazan MTT  (Sigma, St. Louis,
O) for 3–4 h.
.7. Vaccine formulation
SH1-VLPs  were prepared in three different concentrations
n PBS as per HA content (3 g, 0.3 g and 0.03 g SH1-HA
er 50 L vaccine dose). The AH1-VLP vaccine was  prepared
t a single concentration (0.3 g AH1-HA per 50 L). M1-VLPs
erved as a negative control and were adjusted to a total pro-
ein concentration equal to that of SH1-VLP (0.3 g HA content)
s measured using the Quickstart Bradford Dye Reagent (Bio-
ad, Hercules, CA) with bovine serum albumin as standard.
he content of infectious baculovirus per g HA varied slightly
etween 1.03 × 107 and 2.62 × 107 pfu (plaque forming units).
ll vaccine doses including the M1-only VLP negative control
ontained similar doses of infectious baculovirus (Suppl. Table
). For further characterisation the migration pattern of the
LPs into a sucrose gradient was analysed by ultracentrifugation
Suppl. Fig. 1).
.8.  Mouse immunisation and challenge
Animal experiments were performed using 6–8 week-old
emale BALB/c mice (Jackson Laboratories) according to the guide-
ines of the Icahn School of Medicine at Mount Sinai Institutional
nimal Care and Use Committee (permit LA12-00028). Animals had
ree access to food and water and were kept on a 12-h light/dark
ycle. Mice were anesthetised by intraperitoneal (IP) injection of
.1 mL  of a ketamine/xylazine mixture (0.15 mg/kg and 0.03 mg/kg)
efore intranasal procedures. The prime-only group was  immu-
ised once with SH1-VLPs at a dose of 0.03 g, 0.3 g or 3 g
ased on HA content in PBS or with 0.3 g AH1-VLPs in a volume
f 50 L intramuscularly (i.m.) in the calf muscle (N = 5 per vac-
ine dose) at day 0. The prime-boost group (N = 5) was immunised
wice with 0.3 g SH1-VLPs, at an interval of 14 days. A control
roup (N = 5) was immunised once with M1-only VLPs at a total
rotein concentration equal to that of the SH1-0.3 g vaccine dose.
D8+-depleted prime-only groups received one immunisation with
.3 g SH1- or M1-VLPs (N = 5) and were treated by IP injection
f 300 g of anti-CD8+ T-cell antibody [25] (from hybridoma line
.43) for CD8+ T-cell depletion 48 and 24 h prior to challenge.
aive mice (N = 5 per group) were included as additional nega-
ive control group. Three weeks after the last immunisation blood
as drawn from anesthetised mice by submandibular bleeding.
ice were then infected with 100 LD50 of the recombinant virus
R8:SH1. Weight loss was monitored daily for up to 14 days and
nimals that lost 25% or more of their initial body weight were
cored dead and humanely euthanised, according to institutional
uidelines.e 32 (2014) 355– 362 357
2.9. ELISA assays
A  quantitative ELISA was performed to assess titres of HA-
speciﬁc IgG. Sera (N = 5) from the different vaccine groups were
pooled and assayed in duplicate. HA proteins of representa-
tives of all inﬂuenza A group 2 subtypes were recombinantly
expressed with a C-terminal T4 foldon trimerisation domain
and an N-terminal His-tag as described in [23] and used
as antigens (HAs from A/Shanghai/1/13 (H7N9, abbrevi-
ated SH1), A/Anhui/1/13 (H7N9, AH1), A/mallard/NL/12/00
(H7N3,  malNL00), A/rhea/North Carolina/39482/93 (H7N1,
rheaNC93), A/chicken/Jalisco/12283/12 (H7N3, chickJal12),
A/Hong Kong/1/68 (H3N2, H3), A/duck/Czech/56 (H4N6,
H4), A/mallard/Interior Alaska/10BM01929/10 (H10N7, H10),
A/mallard/Gurjev/263/82 (H14N5, H14), A/wedge tailed
shearwater/Western Australia/2576/79 (H15N9, H15) and
A/California/04/09 (pandemic H1N1, pH1)).
Brieﬂy, Immulon 4HBX® ultra-high-binding polystyrene plates
(Thermo Fisher Scientiﬁc, Waltham, MA)  were coated with rHA at a
concentration of 2 g/mL in coating buffer (0.1 M Na2CO3/NaHCO3,
pH 9.2, 50 L/well) at 4 ◦C overnight. Plates were blocked with
PBST and 3% (w/v) non-fat dry milk for 2 h at room temper-
ature. Plates were incubated with 3-fold dilutions to endpoint
titre of pooled serum samples (100 L per well in PBST with 1%
non-fat dry milk (starting concentration: 1:50 dilution) for 2 h
at room temperature. Following three washes with 100 L PBST,
plates were incubated with horseradish-peroxidase-conjugated
anti-mouse IgG (Santa Cruz Biotechnology, Dallas, TX) at a dilu-
tion of 1:3000 in PBST and non-fat dry milk (1%, v/v) for 1 h
at room temperature. Unbound antibody was removed by three
washes with 100 L PBST and plates were developed using Sig-
maFAST OPD substrate (Sigma, St. Louis, MO)  (100 L/well) and
stopped with 3 M HCl (50 L/well). The colorimetric change was
measured as the optical density (OD 490 nm) on a Synergy 4
(BioTek, Winooski, VT) microplate reader. The endpoint titre was
deﬁned as the reciprocal of the highest dilution that yields an
OD-value above the mean plus three standard deviations of blank
wells.
2.10. Hemagglutination inhibition assay
The hemagglutination inhibition (HI) assay was used to assess
functional antibodies to the HA able to inhibit agglutination of
turkey red blood cells (tRBCs). Serum samples were treated with
4 volumes of a receptor-destroying enzyme of Vibrio cholera ﬁl-
trate (Sigma, St. Louis, MO)  for 18 h at 37 ◦C. After addition of 3
volumes of 2.5% (v/v) sodium citrate, the serum samples were
incubated at 56 ◦C for 30 min  and diluted with PBS to yield a
1:10 dilution of the original serum sample. Serum samples were
2-fold serially diluted in PBS (25 L sample volume) in Nunc®
96-well polystyrene V-bottom microwell plates (Thermo Fisher
Scientiﬁc, Waltham, MA)  and then incubated with recombinant
reassortant virus (PR8:AH1, PR8:SH1, PR8:malNL00, PR8:malAlb01
or PR8:chickJal12) at 4 HAU/25 L in PBS for 30 min  at room
temperature. Then, 50 L 0.5% tRBCs (Lampire Biological Labora-
tory, Pipersville, PA) were added and the mixture was incubated
for 45 min  at 4 ◦C. Sera from all groups were assayed individu-
ally for the challenge strain PR8:SH1 for HI activity. Divergent H7
strains were assayed with pooled sera. The HI titre was calculated
from the reciprocal of the highest dilution that completely inhib-
ited hemagglutination of red blood cells and the geometric mean
titre (GMT) of two independent assays was reported as the ﬁnal
titre. Two  negative HI readings were assigned <10, single negative
results were scored a value of 5 for the calculation of geometric
means.
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. Results
.1. Efﬁcacy of H7-VLPs in an in vivo mouse challenge experiment
In preparedness for a potential H7N9 pandemic, it is highly
esirable, not only for vaccine manufacturers, but also for health
are providers, to develop an inﬂuenza vaccine that at low vaccine
ose, most preferably with a single administration, stimulates good
mmune responses. In a previous study by Margine and colleagues
16] showed that residual baculovirus in VLP formulations enhance
he immunogenicity of the vaccine due to potent stimulation of the
nnate immune response and by biasing IgG isotype distribution to
he more active IgG2 subtype.
Thus,  we evaluated whether unadjuvanted single immunisa-
ions with low doses of our VLP-vaccine containing baculovirus
ere effective in eliciting protective immune responses in an in vivo
ouse experiment using a stringent 100 mLD50 challenge dose. We
ssessed protection conferred by three different concentrations of
H1-VLPs (3 g, 0.3 g and 0.03 g in terms of HA content, admin-
stered intramuscularly). We  also compared groups that received
 single vaccine dose with a group that received two  immunisa-
ions on days 0 and 14 (0.3 g in terms of HA content). To explore
hether a prime-only strategy could protect against a heterologous
train as well, we included a VLP formulation that contained HA of
H1, a divergent H7N9 isolate. [4]. Mice that received two  immu-
isations with 0.3 g SH1, expectedly showed a 100% survival rate
nd little weight loss (Fig. 1A and C). Similarly, no weight loss was
bserved for the SH1-3 g prime-only group. Mice in the prime-
nly vaccination groups that received lower vaccine doses (0.3 g
nd 0.03 g) showed more weight loss (7% and 10%, respectively)
han mice in the high dose or prime-boost groups (both 3%), but
he mice were completely protected from mortality and regained
eight after day 5 post challenge (Fig. 1A and C). Mice vaccinated
ith AH1-VLPs lost slightly more weight than mice that received
he same dose of SH1-VLPs (0.3 g of HA) but were fully protected
rom mortality (Fig. 1A and C). Animals that received an M1-only
reparation containing similar amounts of baculovirus as the SH1-
nd AH1-VLP preparation showed no enhanced protection as com-
ared to naïve mice (Fig. 1A and C). This proves that neither M1  or
he baculovirus or a combination of both was able to induce signif-
cant protective immune responses in our challenge model. Since
revious studies highlight the critical role of CD8+ T-cells in protec-
ive immunity to inﬂuenza infection [26,27], we assessed whether
 single low vaccine dose could also induce full protection in CD8+
-cell-depleted mice. Minimal weight loss for CD8+-depleted, SH1-
.3 g-vaccinated mice after challenge and a 100% survival rate
Fig. 1B and D) suggested that the humoral response was  sufﬁcient
o robustly protect these animals.
.2. H7 VLP vaccines induce broadly reactive antibodies
As previous studies reported a remarkable cross-reactivity of
7 antibodies [13,28], we tested sero-reactivity to a panel of diver-
ent recombinant H7 proteins and a representative HA from each
nﬂuenza subtype (H3, H4, H10, H14 and H15 – in addition to H7)
hat cluster into phylogenetic group 2 (Fig. 2A). An H1 HA (group 1)
as added as a negative control antigen. Strong sero-reactivity was
etected against the HA of the vaccine strains SH1 and AH1. Other
epresentative strains of the Eurasian lineage (malNL00) and more
ivergent H7 strains from the North American lineage (rheaNC99,
hickJal12) showed endpoint titres only up to 3-fold lower than
ere achieved with the HA of the vaccine strain (Fig. 2B). Good cor-
elation could be drawn between vaccine dose and total IgG levels
o homologous and heterologous H7 strains as seen by the dose-
ependent decrease of antibody levels in most cases. Moreover,e 32 (2014) 355– 362
we  could detect considerable cross-reactivity against subtypes H15
and H3 across all tested sera.
3.3. H7 VLPs induce cross-reactive HI active antibody responses
Levels  of neutralising antibodies elicited by each vaccine were
measured by hemagglutination inhibition (HI) assay in which sera
from vaccinated mice were evaluated for their ability to prevent
virus-induced agglutination of turkey RBCs. Results show that the
VLP-based H7 vaccine induced high HI-active antibody titres up
to 1:40 for PR8:SH1 and up to 1:80 against PR8:AH1 (Table 1).
Both VLP vaccines were also able to induce levels of HI antibod-
ies that prevented virus-induced hemagglutination by a panel of
divergent H7 strains of the Eurasian and the more distant North
American lineage, with titres of up to 1:40. Single vaccination with
the two higher SH1-VLP vaccine doses (3 g and 0.3 g) gener-
ated similar amounts of HI-active antibodies for all tested virus
strains and negligible HI titres were measured for the lowest vac-
cine dose (0.03 g). The second dose of SH1-VLP vaccine led to a
2-fold enhancement of average levels of HI-active antibodies for
most of the virus strains tested. No HI antibodies were detected in
the two control groups (naïve and M1-vaccinated mice).
4.  Discussion
On 31 March 2013, the Chinese Health and Family Planning
Commission notiﬁed the WHO  of three cases of human infections
with a novel inﬂuenza A (H7N9) strain [1], which has been the
causative agent for 137 infections with a mortality rate of 33% as
of 25 October. It remains unclear whether the virus will persist in
the human reservoir and cause sporadic infections, or whether it
will gain the ability to transmit from human to human through
mutations or re-assortment [29]. Limited reports on new human
incidences might be due to the shutdown of live poultry mar-
kets throughout the country. However, H7N9 may  also follow a
seasonal outbreak pattern similar to H5N1, therefore an epidemic
could re-occur in fall [30]. Since no vaccine for H7N9 is available
for humans, antivirals are the only treatment options, but bear the
risk to yield treatment-resistant viruses, which were already asso-
ciated with poor clinical outcome [6,7]. The potential threat of a
pandemic outbreak serves as catalyst for enhanced research and
vaccine development efforts in both academia and industry. Human
H7 vaccines are underway and have been evaluated in preclinical
[8–11,13,14,31,32] or phase I or I/II studies [12,33–35]. However,
most H7 vaccines showed low immunogenicity in humans and
might not be able to raise titres of HI-active antibodies in the protec-
tive range [34,35]. Furthermore, the overall majority of H7  vaccines
in the pipeline are focused on egg-based production which might
be an inadequate platform in a pandemic setting due to limited
manufacturing capacities and longer production times compared
to cell-culture based systems. Based on predictions that consider
the current maximum global capacity for inﬂuenza virus vaccine
manufacturing vaccine production will be too slow to adequately
meet the needs for a vaccine in the event of a pandemic [36].
A major factor limiting the manufacturing capacity of a vaccine
is the minimum immunogenic antigen dose that confers protec-
tion. It is highly desirable to obtain good efﬁcacy already with
low vaccine doses and the fewest possible injections to prevent
shortages. Development of more efﬁcient vaccines is a key objec-
tive deﬁned by the Global Action Plan for Inﬂuenza vaccines by
the WHO  [37].Here,  we chose to evaluate a low-dose single-shot VLP vac-
cine against the novel H7N9 virus. Single immunisation with as
low as 0.03 g SH1-VLP preparation (based on HA content) could
confer full protection against a stringent homologous challenge
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Fig. 1. VLP vaccines protect against lethal H7N9 challenge in mice. Mice (N = 5 per group) were intramuscularly vaccinated with the following vaccine preparations and
were  intranasally challenged with 100 mLD50 of A/Shanghai/1/13. Weight loss (A and B) and survival rates (C and D) were monitored for 14 days post challenge. BALB/c
mice received one dose of the vaccine preparation intramuscularly on day 0 of SH1-VLPs with a HA content of 3 g (dark blue), 0.3 g (signal blue), 0.03 g (light blue),
AH1-VLPs containing 0.3 g HA (pink), M1-VLPs at a total protein concentration equal to that of SH1-0.3 g VLPs (dark green) or were not vaccinated (black). Another group
of  mice received two vaccinations at days 0 and 14 with 0.3 g SH1-VLPs (orange). Control groups were either vaccinated with 0.3 g SH1-VLPs (signal blue, open squares)
or M1-VLPs (dark green, open circles) and were CD8+ T-cell depleted by antibody treatment 48 h and 24 h pre challenge and weight loss (B) and survival (D) were followed
for  14 days. The weight loss curves represent the mean percentage of the group initial body weight and error bars indicate the standard deviation. Grey baselines (A and B)
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vndicate the weight cut-off of 75% of the initial body weight at which mice were hu
oss of undepleted SH1-0.3 g-vaccinated mice to allow for comparison of weight l
100 mLD50) in BALB/c mice (Fig. 1C). Mice that were vaccinated
ith a single vaccine dose of 3 g SH1-VLP did not show anyign of disease. This is in contrast to an earlier study by Smith
t al. who reported that mice vaccinated with a two dose regi-
en with 0.7–2 g lost 10–15% of their initial body weight after
able 1
I  antibody titres induced by vaccination with various H7-VLP vaccine doses.
Vaccine groupa HI titre (1:X) against recombinant virus strainsd
PR8:SH1b PR8:AH1c
Naïve <10.0 (all <10) <10.0 
SH1-3 g 15.2 (10–40) 40.0 
SH1-0.3 g 15.2 (10–20) 40.0 
SH1-0.03 g 5.7 (<10–10) 10.0 
AH1-0.3 g 10.0 (<10–20) 20.0 
SH1-0.3 g boost 20.0 (10–40) 80.0 
M1  <10.0 <10.0 
a Mice (N = 5 per group) were immunised once intramuscularly with SH1-VLPs or AH-1
oost)  received two vaccine doses with the indicated HA content. Control groups were n
qual to the SH1-0.3 g-VLPs vaccine dose.
b Sera from individual mice were assayed for A/Shanghai/1/13 (SH1). Shown are the ge
c HI titres for divergent H7 strains were assayed with pooled sera in duplicates.
d HI titres are expressed as the reciprocal of the highest dilution of serum that compl
itrated viruses (PR8:SH1, PR8:AH1, PR8:malNL00, PR8:malAlb01 and PR8:chickJal12). HI
ere both negative, the HI titre was assigned as <10. Single negative results in a duplicate
alue.  The range of the duplicate measurements is given in brackets if it yielded two diffey euthanised. The signal blue baselines in (A and B) indicate the maximum weight
etics with the CD8+ T-cell depleted mice that received the same vaccine dose.
a  3.5 LD50 challenge [14]. Since the VLPs used in their study were
highly puriﬁed we would speculate that active baculovirus con-
taminants in our vaccine preparations (supplementary data) acted
as an adjuvant and boosted the immune response – an effect that
was reported before. It was shown that baculovirus can enhance
PR8:malNL00c PR8:malAlb01c PR8:chickJal12c
<10.0 <10.0 <10.0
10.0 20.0 10.0
10.0 20.0 10.0
<10.0 7.1 (<10–10) <10.0
10.0 20.0 7.1 (<10–10)
20.0 28.3 (20–40) 10.0
<10.0 <10.0 <10.0
VLPs at indicated concentrations based on the HA content. One group (SH1-0.3 g
aive mice or mice vaccinated once with M1-VLPs at a total protein concentration
ometric mean and the range (in brackets).
etely inhibited agglutination of turkey red blood cells by four HA units of the ﬁve
 titres are indicated as geometric mean values. In case the duplicate measurements
 measurement were assigned a value of 5 for the calculation of the geometric mean
rent values.
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Fig. 2. VLP vaccines induce broadly reactive antibodies in mice. Sera from vaccinated mice were assayed for antibody endpoint titres against representatives of all group 2
HAs  and one H1 HA (group 1). (A) Phylogenetic analysis was performed with the two vaccine strains (red), another representative of the H7 Eurasian lineage (pink), more
divergent HAs from the North American lineage (purple) and other HA representatives of group 2 and group 1 (both black) that were evaluated in the ELISA. Phylogenetic
trees were constructed using the CLUSTAL W algorithm using the neighbour-joining method and visualised with FigTree. (B) Samples were from mice (N = 5) immunised with
a  single dose of SH1-VLPs containing 3 (dark blue), 0.3 (signal blue) or 0.03 g HA (light blue), AH1-VLPs (pink) with a HA-content of 0.3 g, two doses of SH1-VLPs (orange;
days 0 and 14) with a HA-content of 0.3 g or M1-VLPs (dark green) administered at a total protein concentration equal to the SH1-0.3 g vaccine dose. Mice were bled 35
days  post prime or 21 post boost respectively and assayed for the indicated panel of rHAs. Pooled serum was  used to assess reactivity to the eleven different HAs. Values
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cepresent the geometric mean of the calculated end point titres (read-outs subtra
rror of the mean. The green baseline indicates background levels of serum from m
mmunogenicity of VLP vaccines through boosting the immune
esponse by interferon-signalling and biasing IgG isotype distribu-
ion [16]. Vaccination with VLPs harbouring an HA from a closely
elated (but phylogenetically distinct) H7 strain, A/Anhui/1/13, also
rotected mice from PR8:SH1 challenge after only one immunisa-
ion.
Generally, T-lymphocytes have long been appreciated as a criti-
al contributor to protection and recovery from inﬂuenza infection
38]. Essentially, CD8+ T-cells play an important role in the clear-
nce of virus infected cells and thereby limit viral replication,
isease development and reduce mortality [26,38,39]. We  tended
o address the importance of the cytotoxic immune response medi-
ted by CD8+-cells in our challenge experiment. CD8+-depleted
ice were fully protected in the challenge experiment and showed
imilar weight loss kinetics as observed for non-depleted mice
Fig. 1B and D), which is in agreement with previous ﬁndings [40].
owever, in a recent work by Hemann et al. [26], only 60% survival
f CD8+-depleted mice that received a single dose of an inﬂuenza
1-VLP vaccine was reported in a homologous challenge experi-
ent after intranasal vaccination with 2.5 g VLPs. This suggestshat our VLP preparation induces sufﬁciently high titres of neutral-
sing antibodies, even at low single vaccine doses of 0.03–0.3 g
LP, to be protective in a stringent homologous and heterologous
hallenge. A contribution of virus-speciﬁc CD8+-cells to protectiony the mean and three-fold standard deviation) and error bars depict the standard
at received the M1-VLP (no HA included).
from  infection might be redundant in this case. As the delivery route
of VLPs was shown to inﬂuence the strengths of the humoral and
cellular immune response [16,41], one might speculate whether
the survival rate would have been higher in the study of Hemann
et al. [26], if an alternative to the intranasal vaccination route was
chosen.
Single immunisations with our vaccine could induce antibodies
that were reactive to all heterologous H7 subtypes tested (Fig. 2), in
agreement with an earlier study [13]. We  could also demonstrate
signiﬁcant reactivity to other members of group 2 HAs, such as the
phylogenetically related H15 subtype and the more divergent H3
HA. Interestingly, cross-reactivity to H10, which is phylogenetically
closer to H7 than H3, was  only slightly above the background signal
for the 3 g dose group (Fig. 2), which is in agreement with results
recently obtained by Muramatsu and colleagues [42]. It was pre-
viously shown that vaccination with different immunogens that
vary only in their globular head region, speciﬁcally could boost
the stalk-reactive antibody response in mice [22,43]. However,
both our immunisations for the prime-boost group were per-
formed with the same immunogen and we assume that the boost
in sero-reactivity primarily results from head-speciﬁc antibodies.
We therefore investigated the activity of the elicited antibodies by
a hemagglutination inhibition assay with a panel of H7 strains. HI-
active antibodies could be detected for the vaccine strains but also
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or a panel of divergent H7 viruses, which included representatives
f the Eurasian and the North American lineage (Table 1). These
esults are in good agreement with those from Abbas et al. [44]
btained in chicken and Goff et al. [13] and Smith et al. [14] obtained
n mice. We  detected lower HI-activity for the PR8:SH1 virus than
or PR8:AH1, even for the groups immunised with SH1-VLPs. This
ay  be due to the utilisation of individual versus pooled sera in
he assays. Although virus preparations were standardised, there
till might have been slight variations in HA-activity of the viruses
tilised. The second immunisation leads to a two-fold increase in
I titres for almost all tested virus strains. The observed HI crossre-
ctivity might be the result of the completely conserved antigenic
ite A of Eurasian and North American lineage H7 viruses [13]. It
s of note that even the group that received the lowest VLP dose of
.03 g and had only neglectable HI-activity was completely pro-
ected from challenge, suggesting that detectable levels of HI-active
ntibodies might not be required for protection.
. Conclusion
Here we show full protection of mice vaccinated with low
oses of an H7-VLP vaccine based on the HA antigens of the
ovel H7N9 strains in a one-shot vaccination strategy from a
tringent lethal challenge with an H7N9 virus. Furthermore, these
LPs induced broad sero- and HI-reactivity. Based on this data we
peculate that the vaccine could also protect against other, diver-
ent H7 strains. We  have previously shown that the presence of
ctive baculovirus in insect cell-derived VLP preparation is able to
ubstantially increase immunogenicity and protection due to its
mmune-stimulatory capability [16]. We  would assume that they
lay a substantial role in the efﬁcacy and potent immunogenicity
f the H7 VLP vaccine tested here. VLP vaccines that contain bac-
loviruses might prove to be useful in pandemic situations where
arge quantities of highly effective vaccines are needed. However,
ioactive, live viruses in vaccine formulations might induce strong
eactogenicity and safety concerns might prevent their applica-
ion in humans. Importantly, a bioactive baculovirus component
f a vaccine would need to be standardised and tested for stability
nder different storage conditions. In addition it would be neces-
ary to assess the minimum effective concentration of baculovirus
n a vaccine dose and to establish an acceptable HA or VLP to active
aculovirus ratio. Assessment of the latter ratio might be difﬁcult
ue to the presence of baculovirus–VLP hybrids – baculovirus par-
icles that incorporate HA and VLPs that incorporate baculovirus
apsid and envelope proteins [45,46]. As a large body of research
s currently focusing on baculovirus-based expression systems in
accine manufacturing, more safety data will accumulate and more
nalytical methods will become available for this system in the near
uture [46,47] and might possibly spur its establishment in human
pplications.
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